{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-114891","form_type":"8-K","ticker":"SLNO","cik":"0001484565","company_name":"SOLENO THERAPEUTICS INC","filed_at":"2025-05-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.424134+00:00","generated_at":"2026-05-22T07:39:40.673548+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Soleno Q1 net loss $43.8M; VYKAT XR launch: 268 patient forms, 131 prescribers","bullets":["VYKAT XR approved by FDA Mar 26; treatments started Apr 14; 268 patient start forms and 131 prescribers through May 6.","Q1 net loss $43.8M ($0.95 EPS) vs $21.4M ($0.59) a year ago; no revenue yet.","Cash and marketable securities $290.0M; operating cash use $32.8M in quarter.","R&D expense $13.5M; SG&A $29.3M, reflecting launch preparation costs.","MAA submission to EMA for DCCR on track for Q2 2025; contingent consideration liability $17.8M."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-114891","json":"https://secwatch.observer/filing/0001193125-25-114891.json","markdown":"https://secwatch.observer/filing/0001193125-25-114891.md","text":"https://secwatch.observer/filing/0001193125-25-114891.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1484565/000119312525114891/0001193125-25-114891-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1484565/000119312525114891/d56501d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T07:39:40.673548+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}